Estrogen News and Research

Latest Estrogen News and Research

Soy food beneficial for women with breast cancer

Although there is a concern regarding the safety of soy food consumption among breast cancer survivors, researchers have found that women in China who had breast cancer and a higher intake of soy food had an associated lower risk of death and breast cancer recurrence, according to a study in the December 9 issue of JAMA.

9 Dec 2009

Xanthohumol compound may aid in preventing prostate cancer

The natural compound xanthohumol blocks the effects of the male hormone testosterone, therefore aiding in the prevention of prostate cancer.

9 Dec 2009

Soy food associated with lower risk of death and breast cancer recurrence, says new study

Researchers at Vanderbilt-Ingram Cancer Center, led by Xiao Ou Shu, M.D., Ph.D., professor of Medicine, have found that a higher intake of soy foods was associated with a lower risk of death and breast cancer recurrence among breast cancer patients in China. The study is published in the December 9 issue of JAMA.

9 Dec 2009

Neuroscientists suggest risky therapy for aging brain may be avoidable by focusing on hormone target

Estrogen seems to act like a middleman in its positive effect on the brain, raising the possibility that future drugs may bypass the carcinogenic hormone altogether while reaping its benefits.

8 Dec 2009

Turmeric and pepper may play a role in preventing breast cancer

A new study finds that compounds derived from the spices turmeric and pepper could help prevent breast cancer by limiting the growth of stem cells, the small number of cells that fuel a tumor's growth.

8 Dec 2009

Social isolation and stress can raise breast cancer risk

Social isolation and related stress could contribute to human breast cancer susceptibility, research from a rat model designed at the University of Chicago to identify environmental mechanisms contributing to cancer risk shows.

8 Dec 2009

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Gloucester Pharmaceuticals announced today the presentation of positive data from an analysis of ISTODAX® (romidepsin) in a subset of patients from Gloucester’s registration study in cutaneous T-cell lymphoma (CTCL) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

7 Dec 2009

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

Gloucester Pharmaceuticals announced today the presentation of preclinical data demonstrating that the combination of ISTODAX® (romidepsin) and Velcade® (bortezomib) resulted in synergistic anti-tumor activity in B-cell non-Hodgkin's lymphoma cell lines.

7 Dec 2009

Positive final data from Phase 2 study of ISTODAX presented

Gloucester Pharmaceuticals announced today the presentation of positive final data from a Phase 2 study of ISTODAX® (romidepsin) in peripheral T-cell lymphoma (PTCL) conducted by the National Cancer Institute (NCI) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

6 Dec 2009

Genomic Health to present its Oncotype DX multi-gene expression test studies at the 32nd SABCS

Genomic Health, Inc. today announced that the company will present results from five studies at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), taking place December 9-13, 2009, at the Henry B. Gonzalez Convention Center.

5 Dec 2009

Pfizer to present study findings from its expanded breast cancer portfolio

Pfizer Oncology announced today that it will be presenting study findings evaluating several compounds including those from its newly expanded breast cancer portfolio following the recent acquisition of Wyeth, focusing on the needs of multiple breast cancer patient populations at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) being held December 9 – 13.

4 Dec 2009

Amgen/GSK's Prolia will be preferred as second- or third-line therapy for osteoporosis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed clinicians say they will use Amgen/GlaxoSmithKline's Prolia as either a second- or third-line therapy for osteoporosis if the drug receives regulatory approval for the indication.

4 Dec 2009

Researchers discover mechanism that explains how chromosomal translocations are not random

Researchers at the UC San Diego School of Medicine have pinpointed a mechanism that may help explain how chromosomal translocations - the supposedly random shuffling of large chunks of DNA that frequently lead to cancer - aren't so random after all. They have developed a model of such chromosomal mix-ups in prostate cancer which indicates that the male sex hormone (androgen) receptor unexpectedly plays a key role in driving specific translocations in the development of cancer.

4 Dec 2009

ISTODAX included in the updated NCCN Clinical Practice Guidelines in Oncology

Gloucester Pharmaceuticals announced today that ISTODAX® (romidepsin) has been included in the updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™ as a suggested systemic treatment option for patients with mycosis fungoides and Sézary syndrome—two of the most common types of cutaneous T-cell lymphoma (CTCL).

4 Dec 2009

Survey and existing research reveal differences in pain management between genders

For many Canadians, December is the start of the holiday season and a time of joy and celebration, but for some, it can also be a time of increased aches and pains. Whether it's a backache from shoveling away the first snowfall, hanging holiday lights or a headache from the stress of holiday shopping, December brings a new set of aches and pains.

2 Dec 2009

Anti-Aging Institute of California offers 'Don't Pause' to get rid of menopause symptoms

Menopause - it's an unavoidable part of aging as a woman, and brings with it a host of uncomfortable symptoms that negatively impact quality of life. Hot flashes, poor sleep, mood swings, weight gain, night sweats and lethargy are just some of the life-altering symptoms of menopause and perimenopause.

30 Nov 2009

Merck to commence MK-6913 phase IIa efficacy trial for treatment of hot flashes/hot flushes

The Swedish biotech company Karo Bio today announced that Merck & Co., Inc., through an affiliate, plans to enter a clinical phase IIa trial with the collaboration's lead investigational drug candidate, MK-6913, identified as part of their joint research collaboration. No milestone payment to Karo Bio is associated with the initiation of phase II clinical development.

26 Nov 2009

Alpha-fetoprotein, a well-tolerated agent for treatment and prevention of breast cancer

Researchers have found that hormones produced during pregnancy induce a protein that directly inhibits the growth of breast cancer. This protein, alpha-fetoprotein (AFP), may serve as a viable, well-tolerated agent for the treatment and prevention of breast cancer, according to findings published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

25 Nov 2009

LRI awards $3.6 million grants to drive innovative science in lupus and related diseases

The Lupus Research Institute (LRI) today named 12 new grant recipients for 2009. The awards, totaling $3.6 million, recognize innovative work across a broad spectrum of lupus research. All were selected for their creativity, novelty, and potential to drive scientific discovery to ultimately prevent, treat, and cure the complex disease of systemic lupus.

24 Nov 2009

U.S. Court rules in Merck's favor in Flemings case involving FOSAMAX

Merck said today that U.S. District Court Judge John F. Keenan granted summary judgment in Merck's favor in Flemings v. Merck. Flemings is the second of three cases involving FOSAMAX (alendronate sodium) designated by the federal MDL court as a bellwether trial case.

24 Nov 2009

Estrogen News and Research

Latest Estrogen News and Research

Soy food beneficial for women with breast cancer

Xanthohumol compound may aid in preventing prostate cancer

Soy food associated with lower risk of death and breast cancer recurrence, says new study

Neuroscientists suggest risky therapy for aging brain may be avoidable by focusing on hormone target

Turmeric and pepper may play a role in preventing breast cancer

Social isolation and stress can raise breast cancer risk

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

Positive final data from Phase 2 study of ISTODAX presented

Genomic Health to present its Oncotype DX multi-gene expression test studies at the 32nd SABCS

Pfizer to present study findings from its expanded breast cancer portfolio

Amgen/GSK's Prolia will be preferred as second- or third-line therapy for osteoporosis

Researchers discover mechanism that explains how chromosomal translocations are not random

ISTODAX included in the updated NCCN Clinical Practice Guidelines in Oncology

Survey and existing research reveal differences in pain management between genders

Anti-Aging Institute of California offers 'Don't Pause' to get rid of menopause symptoms

Merck to commence MK-6913 phase IIa efficacy trial for treatment of hot flashes/hot flushes

Alpha-fetoprotein, a well-tolerated agent for treatment and prevention of breast cancer

LRI awards $3.6 million grants to drive innovative science in lupus and related diseases

U.S. Court rules in Merck's favor in Flemings case involving FOSAMAX

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Estrogen News and Research

Latest Estrogen News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in